Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081532" target="_blank" >RIV/00023001:_____/21:00081532 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11120/21:43921736 RIV/00216208:11110/21:10428717
Výsledek na webu
<a href="https://reader.elsevier.com/reader/sd/pii/S0009898121002242?token=4549504FDD6D7905649FE024B39DC34F1805DB4CA1E1742B21A8AD8A46BFEE5DB8E015E988BB117318D40C4DFDAB08B1&originRegion=eu-west-1&originCreation=20211012094704" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0009898121002242?token=4549504FDD6D7905649FE024B39DC34F1805DB4CA1E1742B21A8AD8A46BFEE5DB8E015E988BB117318D40C4DFDAB08B1&originRegion=eu-west-1&originCreation=20211012094704</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.cca.2021.06.023" target="_blank" >10.1016/j.cca.2021.06.023</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
Popis výsledku v původním jazyce
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL receptors. Inhibition of PCSK9 increase uptake of LDL-particles and pathogen-associated molecular patterns (PAMPs). The aim of our study was to evaluate biological variation of serum PCSK9. Methods: Within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a 6-week protocol (7 samples, equidistant time intervals). Serum concentration of PCSK9 was measured by a Quantikine ELISA assay (R&D systems, Bio-Techne Ltd., UK) on a DS2 ELISA reader (Dynex Technologies GmbH, Germany). Precision (CVA) was assessed by duplicate measurements. Two methods with different levels of robustness were used for the estimation of CVI, SD-ANOVA and CV-ANOVA method. We calculated the index of individuality and reference change values. The experiment was fully compliant with EFLM database checklist. Results: The within-subject values of PCSK9 in healthy persons, as calculated by two statistical methods, were 23.2% (SD-ANOVA with CVA of 5.6%) and 26.6% (CV-ANOVA with CVA of 4.8%). The CVG was 10.9% (SDANOVA), index of individuality and RCV were 2.13 and 66.3%, respectively. Conclusions: The high index of individuality indicates that common reference intervals can be used to interpret serum PSCK9 values.
Název v anglickém jazyce
Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
Popis výsledku anglicky
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL receptors. Inhibition of PCSK9 increase uptake of LDL-particles and pathogen-associated molecular patterns (PAMPs). The aim of our study was to evaluate biological variation of serum PCSK9. Methods: Within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a 6-week protocol (7 samples, equidistant time intervals). Serum concentration of PCSK9 was measured by a Quantikine ELISA assay (R&D systems, Bio-Techne Ltd., UK) on a DS2 ELISA reader (Dynex Technologies GmbH, Germany). Precision (CVA) was assessed by duplicate measurements. Two methods with different levels of robustness were used for the estimation of CVI, SD-ANOVA and CV-ANOVA method. We calculated the index of individuality and reference change values. The experiment was fully compliant with EFLM database checklist. Results: The within-subject values of PCSK9 in healthy persons, as calculated by two statistical methods, were 23.2% (SD-ANOVA with CVA of 5.6%) and 26.6% (CV-ANOVA with CVA of 4.8%). The CVG was 10.9% (SDANOVA), index of individuality and RCV were 2.13 and 66.3%, respectively. Conclusions: The high index of individuality indicates that common reference intervals can be used to interpret serum PSCK9 values.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Clinica chimica acta
ISSN
0009-8981
e-ISSN
—
Svazek periodika
521
Číslo periodika v rámci svazku
October 2021
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
5
Strana od-do
59-63
Kód UT WoS článku
000685433900008
EID výsledku v databázi Scopus
2-s2.0-85109448377